Replies to post #134558 on Biotech Values

[mcbio]

I guess the INX-189 safety results are good. What about ACHN? Don't they have anything in the same ballpark even in preclinical stage?

ACHN doesn't have any nukes, just PIs and NS5A inhibitors.

[DewDiligence]

I guess the INX-189 safety results are good [because BMY paid $2.5B to acquire INHX].

Maybe. See #msg-75308400.